Literature DB >> 8148684

Consensus on diagnosis and management of primary antibody deficiencies. Consensus Panel for the Diagnosis and Management of Primary Antibody Deficiencies.

H M Chapel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8148684      PMCID： PMC2539608          DOI： 10.1136/bmj.308.6928.581

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  17 in total

1.  Elimination of infectious retroviruses during preparation of immunoglobulins.

Authors:  G Mitra; M F Wong; M M Mozen; J S McDougal; J A Levy
Journal:  Transfusion       Date:  1986 Jul-Aug       Impact factor: 3.157

2.  Primary antibody deficiency and diagnostic delay.

Authors:  J Blore; M R Haeney
Journal:  BMJ       Date:  1989-02-25

3.  Clinical and immunologic analyses of 103 patients with common variable immunodeficiency.

Authors:  C Cunningham-Rundles
Journal:  J Clin Immunol       Date:  1989-01       Impact factor: 8.317

4.  Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA.

Authors:  A W Burks; H A Sampson; R H Buckley
Journal:  N Engl J Med       Date:  1986-02-27       Impact factor: 91.245

5.  High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease.

Authors:  C M Roifman; H Levison; E W Gelfand
Journal:  Lancet       Date:  1987-05-09       Impact factor: 79.321

6.  Primary hypogammaglobulinaemia: impaired lung function and body growth with delayed diagnosis and inadequate treatment.

Authors:  J Björkander; B Bake; L A Hanson
Journal:  Eur J Respir Dis       Date:  1984-10

7.  Immunoglobulin replacement therapy by self-infusion at home.

Authors:  H Chapel; V Brennan; E Delson
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

8.  Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies.

Authors:  J Björkander; L Hammarström; C I Smith; R H Buckley; C Cunningham-Rundles; L A Hanson
Journal:  J Clin Immunol       Date:  1987-01       Impact factor: 8.317

Review 9.  Adverse effects of intravenous immunoglobulin.

Authors:  S A Misbah; H M Chapel
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

10.  Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency.

Authors:  J Björkander; C Cunningham-Rundles; P Lundin; R Olsson; R Söderström; L A Hanson
Journal:  Am J Med       Date:  1988-01       Impact factor: 4.965
View more
  37 in total

Review 1.  Antimicrobial prophylaxis.

Authors:  J Smith; A Finn
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

2.  Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy.

Authors:  U Nicolay; S Haag; F Eichmann; S Herget; D Spruck; A Gardulf
Journal:  Qual Life Res       Date:  2005-09       Impact factor: 4.147

3.  Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study.

Authors:  Ann Gardulf; Uwe Nicolay; Oscar Asensio; Ewa Bernatowska; Andreas Böck; Beatriz Costa Carvalho; Carl Granert; Stefan Haag; Dolores Hernández; Peter Kiessling; Jan Kus; Jaune Pons; Tim Niehues; Sigune Schmidt; Ilka Schulze; Michael Borte
Journal:  J Clin Immunol       Date:  2006-04-26       Impact factor: 8.317

4.  Unnecessary repeat requesting of tests: an audit in a government hospital immunology laboratory.

Authors:  J Kwok; B Jones
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

5.  Impact of a physician education and patient awareness campaign on the diagnosis and management of primary immunodeficiencies.

Authors:  Diana Pickett; Vicki Modell; Ian Leighton; Fred Modell
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

6.  The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.

Authors:  H M Chapel; G P Spickett; D Ericson; W Engl; M M Eibl; J Bjorkander
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

Review 7.  Intravenous immune globulin in primary immunodeficiency.

Authors:  M Haeney
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Carimune NF Liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases.

Authors:  Melvin Berger; Charlotte Cunningham-Rundles; Francisco A Bonilla; Isaac Melamed; Johann Bichler; Othmar Zenker; Mark Ballow
Journal:  J Clin Immunol       Date:  2007-05-04       Impact factor: 8.317

9.  From genotype to phenotype. Further studies measuring the impact of a Physician Education and Public Awareness Campaign on early diagnosis and management of primary immunodeficiencies.

Authors:  Fred Modell; Diana Puente; Vicki Modell
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

10.  Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin.

Authors:  V M Brennan; N J Salomé-Bentley; H M Chapel
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.